| 1 | single | 27,642 |
| 2 | one-time | 119 |
| 3 | 75-g | 81 |
| 4 | 5-ml | 22 |
| 5 | 1-time | 19 |
| 6 | bioenterics | 18 |
| 7 | single-ascending | 15 |
| 8 | 20-g | 14 |
| 9 | full-day | 13 |
| 10 | 2-ml | 11 |
| 11 | 20-ml | 11 |
| 12 | 75-gram | 11 |
| 13 | 5-g | 9 |
| 14 | semi-open | 9 |
| 15 | sub-effective | 9 |
| 16 | 60-ml | 8 |
| 17 | structure-directing | 8 |
| 18 | subhypnotic | 8 |
| 19 | ballpoint | 7 |
| 20 | giraffe | 7 |
| 21 | 2.5-ml | 6 |
| 22 | non-oncology | 6 |
| 23 | subeffective | 6 |
| 24 | 2.3-kb | 5 |
| 25 | 7.5-mm | 5 |
| 26 | 75g | 5 |
| 27 | fixed-flexible | 5 |
| 28 | medium-low | 5 |
| 29 | single-oral | 5 |
| 30 | 1.5-ml | 4 |
| 31 | 15-hour | 4 |
| 32 | benzisoxazole | 4 |
| 33 | germline-specific | 4 |
| 34 | glycine-based | 4 |
| 35 | near-lethal | 4 |
| 36 | risk-accepting | 4 |
| 37 | shofu | 4 |
| 38 | singe | 4 |
| 39 | single-active | 4 |
| 40 | standard-higher | 4 |
| 41 | subantibiotic | 4 |
| 42 | subdepressor | 4 |
| 43 | subterminal | 4 |
| 44 | tumoristatic | 4 |
| 45 | 1,200-mg | 3 |
| 46 | 16-oz | 3 |
| 47 | 2-time | 3 |
| 48 | 30-cycle | 3 |
| 49 | 7.5-µg | 3 |
| 50 | cyclizing | 3 |
| 51 | data-coordinating | 3 |
| 52 | explicative | 3 |
| 53 | hyperfluorescent | 3 |
| 54 | lichrospher | 3 |
| 55 | low-dietary | 3 |
| 56 | multi-compartment | 3 |
| 57 | non-antihypertensive | 3 |
| 58 | nonantidepressant | 3 |
| 59 | nonhypotensive | 3 |
| 60 | p4-releasing | 3 |
| 61 | precurarizing | 3 |
| 62 | response-dependent | 3 |
| 63 | simulation-enhanced | 3 |
| 64 | single-strength | 3 |
| 65 | single-threshold | 3 |
| 66 | six-time | 3 |
| 67 | three-axis | 3 |
| 68 | treatment-blind | 3 |
| 69 | trp-balanced | 3 |
| 70 | -3.00d | 2 |
| 71 | 1.25-mm | 2 |
| 72 | 100-gram | 2 |
| 73 | 1200-kcal | 2 |
| 74 | 14-gy | 2 |
| 75 | 180-microg/kg | 2 |
| 76 | 21-g | 2 |
| 77 | 26-gauge | 2 |
| 78 | 3-day/month | 2 |
| 79 | 3-log10 | 2 |
| 80 | 30-lead | 2 |
| 81 | 4-gy | 2 |
| 82 | 480-khz | 2 |
| 83 | basal-supported | 2 |
| 84 | beta-1-selective | 2 |
| 85 | chain-terminating | 2 |
| 86 | co-suspect | 2 |
| 87 | collodion | 2 |
| 88 | coordinated-delivery | 2 |
| 89 | critical-dose | 2 |
| 90 | demineralising | 2 |
| 91 | downward-pointing | 2 |
| 92 | dsm-iii/iv | 2 |
| 93 | ether-extractable | 2 |
| 94 | first/last | 2 |
| 95 | five-bladed | 2 |
| 96 | flow-type | 2 |
| 97 | four-phasic | 2 |
| 98 | fourth-dose | 2 |
| 99 | high-caliber | 2 |
| 100 | higher-than-replacement | 2 |
| 101 | judo-training | 2 |
| 102 | label-claimed | 2 |
| 103 | lateroventral | 2 |
| 104 | m42 | 2 |
| 105 | market-leading | 2 |
| 106 | megafilling | 2 |
| 107 | microsequential | 2 |
| 108 | microsome-enriched | 2 |
| 109 | multipathogen | 2 |
| 110 | muscle/fat | 2 |
| 111 | near-maximum | 2 |
| 112 | nicotinized | 2 |
| 113 | non-depressor | 2 |
| 114 | nonamplifiable | 2 |
| 115 | p-stim® | 2 |
| 116 | proanthocyanidin-rich | 2 |
| 117 | process- | 2 |
| 118 | reduced/tapering | 2 |
| 119 | rubrene | 2 |
| 120 | single-quadripolar | 2 |
| 121 | single-rising | 2 |
| 122 | size-4 | 2 |
| 123 | sound-head | 2 |
| 124 | species’ | 2 |
| 125 | study-logo | 2 |
| 126 | subpressor | 2 |
| 127 | subpurpuragenic | 2 |
| 128 | target-present | 2 |
| 129 | teflon-lined | 2 |
| 130 | ten-month-old | 2 |
| 131 | therapist-applied | 2 |
| 132 | tong-mai | 2 |
| 133 | too-high | 2 |
| 134 | visual-to-auditory | 2 |
| 135 | wound-irrigation | 2 |
| 136 | 'kneeling | 1 |
| 137 | 'wonder | 1 |
| 138 | +3-line | 1 |
| 139 | 0.25-mg/kg | 1 |
| 140 | 1,300-mg | 1 |
| 141 | 1.5-mg/kg | 1 |
| 142 | 10,000xg | 1 |
| 143 | 10-ng/kg/min | 1 |
| 144 | 10.9-fold | 1 |
| 145 | 100-db | 1 |
| 146 | 100-µg | 1 |
| 147 | 12-μg/kg | 1 |
| 148 | 122-bed | 1 |
| 149 | 1250-bed | 1 |
| 150 | 1300-bed | 1 |
| 151 | 138-mg | 1 |
| 152 | 15-mg/kg/day | 1 |
| 153 | 150,000-iu | 1 |
| 154 | 16-amino-acid | 1 |
| 155 | 1740bp | 1 |
| 156 | 2-bromobenzyl | 1 |
| 157 | 2.5-mcg/kg | 1 |
| 158 | 2.5-mg/kg | 1 |
| 159 | 2.5-yr-old | 1 |
| 160 | 2.5-μg | 1 |
| 161 | 20-ml/kg | 1 |
| 162 | 2200-bed | 1 |
| 163 | 240-minute | 1 |
| 164 | 250-microg | 1 |
| 165 | 256-detector | 1 |
| 166 | 270-bed | 1 |
| 167 | 2990-bed | 1 |
| 168 | 3'-nuclease-resistant | 1 |
| 169 | 3-day-treatment | 1 |
| 170 | 3-microg/kg | 1 |
| 171 | 3-nmol | 1 |
| 172 | 30-session | 1 |
| 173 | 34-mg | 1 |
| 174 | 4,000-u | 1 |
| 175 | 4-hospital | 1 |
| 176 | 4-substituent | 1 |
| 177 | 40-mcg | 1 |
| 178 | 40-microgram/kg | 1 |
| 179 | 45-60-second | 1 |
| 180 | 5,000-u | 1 |
| 181 | 5-propynyl | 1 |
| 182 | 50-iu/kg | 1 |
| 183 | 500-micrograms | 1 |
| 184 | 50ms | 1 |
| 185 | 50μg | 1 |
| 186 | 6-microg/kg | 1 |
| 187 | 6-nmol | 1 |
| 188 | 75-microgram | 1 |
| 189 | 75-unit | 1 |
| 190 | 95-kda | 1 |
| 191 | 955-bed | 1 |
| 192 | afatinib-an | 1 |
| 193 | allylborating | 1 |
| 194 | antipicornavirus | 1 |
| 195 | babysitter | 1 |
| 196 | bb-2 | 1 |
| 197 | beadxpress | 1 |
| 198 | beta-blocker.the | 1 |
| 199 | beta-blocker/sympatholytic | 1 |
| 200 | beta-lactamic | 1 |
| 201 | beta-lowering | 1 |
| 202 | betacytotoxic | 1 |
| 203 | better-assessed | 1 |
| 204 | biflavone | 1 |
| 205 | bolus-loading | 1 |
| 206 | breath-synchronized | 1 |
| 207 | buthanolic | 1 |
| 208 | c.592_593dup | 1 |
| 209 | c7-ketone | 1 |
| 210 | calcium-complexing | 1 |
| 211 | carbamate- | 1 |
| 212 | carbapenem-sparing | 1 |
| 213 | carbon-11-labelled | 1 |
| 214 | caregiver-adolescent | 1 |
| 215 | central-cavity | 1 |
| 216 | chemosensitising | 1 |
| 217 | choriocentesis | 1 |
| 218 | church-organized | 1 |
| 219 | citalopram/escitalopram | 1 |
| 220 | co-spouse | 1 |
| 221 | collagen/epinephrine- | 1 |
| 222 | commoditised | 1 |
| 223 | compressor/nebulizer | 1 |
| 224 | contrast-training | 1 |
| 225 | cooking-course | 1 |
| 226 | corrupting | 1 |
| 227 | corticosteroid-sensitizing | 1 |
| 228 | court-appointed | 1 |
| 229 | cox-2-targeting | 1 |
| 230 | cwep | 1 |
| 231 | cysteine-modifying | 1 |
| 232 | dat-blocking | 1 |
| 233 | day/1 | 1 |
| 234 | dense-sampling | 1 |
| 235 | dettol | 1 |
| 236 | dexmedetomidine- | 1 |
| 237 | dextrose-containing | 1 |
| 238 | diagnodent® | 1 |
| 239 | direct-liquid | 1 |
| 240 | disparity- | 1 |
| 241 | dopamine-receptor-blocking | 1 |
| 242 | doregfp | 1 |
| 243 | double-j-stent | 1 |
| 244 | double-standard | 1 |
| 245 | doxepin-treated | 1 |
| 246 | dsred-monomer | 1 |
| 247 | dtp-hbv | 1 |
| 248 | dtrpa1-c/d | 1 |
| 249 | eudragit®-based | 1 |
| 250 | fa-lowering | 1 |
| 251 | fast-speaking | 1 |
| 252 | fenbendazole-containing | 1 |
| 253 | fetocidal | 1 |
| 254 | fistula/leak | 1 |
| 255 | five-time | 1 |
| 256 | flow-diverter | 1 |
| 257 | fluopyrimidine | 1 |
| 258 | fluorescence- | 1 |
| 259 | fluoroscopy- | 1 |
| 260 | food-tasting | 1 |
| 261 | g3-c12-mediated | 1 |
| 262 | gasoline-equivalent | 1 |
| 263 | geometric-shape | 1 |
| 264 | gfp-hit4 | 1 |
| 265 | glutathione-binding | 1 |
| 266 | gold-containing | 1 |
| 267 | governmentally-led | 1 |
| 268 | grass/rye | 1 |
| 269 | greater-risk | 1 |
| 270 | growth/cell-cycle-suppressing | 1 |
| 271 | gsh-dependent | 1 |
| 272 | gsm-modulated | 1 |
| 273 | gy-full | 1 |
| 274 | harelipped | 1 |
| 275 | health-club | 1 |
| 276 | heroin-abusing | 1 |
| 277 | herpes-infected | 1 |
| 278 | hexadecylamine | 1 |
| 279 | high-affinity-low-capacity | 1 |
| 280 | high-fat/low-fiber | 1 |
| 281 | high-polyunsaturated | 1 |
| 282 | high/luteolytic | 1 |
| 283 | higher-than-equivalent | 1 |
| 284 | human-voiced | 1 |
| 285 | hypergammaglobulinemic | 1 |
| 286 | hypo-echoic | 1 |
| 287 | hypocholestrolemic | 1 |
| 288 | hypolipodemic | 1 |
| 289 | impdh2 | 1 |
| 290 | intravenous/ | 1 |
| 291 | kerosene-based | 1 |
| 292 | knife/gun | 1 |
| 293 | koshu | 1 |
| 294 | laboratory-driven | 1 |
| 295 | laterally-shifted | 1 |
| 296 | leg- | 1 |
| 297 | lensed | 1 |
| 298 | letrozole-to-tamoxifen | 1 |
| 299 | leuko-depleting | 1 |
| 300 | lianous | 1 |
| 301 | light-drinking | 1 |
| 302 | limited-spectrum | 1 |
| 303 | linear-nodular | 1 |
| 304 | linear-plateau | 1 |
| 305 | lombotomy | 1 |
| 306 | low-experience | 1 |
| 307 | low-phonon-energy | 1 |
| 308 | lower-than-approved | 1 |
| 309 | luciferase-based | 1 |
| 310 | macintosh-style | 1 |
| 311 | magnetothermal | 1 |
| 312 | manic/hypomanic/mixed | 1 |
| 313 | mantram-a | 1 |
| 314 | marker-single | 1 |
| 315 | mastery- | 1 |
| 316 | maternal-care | 1 |
| 317 | methanol-chcl3 | 1 |
| 318 | metronidazole/aminoglycoside | 1 |
| 319 | micro-oxidative | 1 |
| 320 | mimivirus-like | 1 |
| 321 | mohel* | 1 |
| 322 | mono/dual | 1 |
| 323 | monoagent | 1 |
| 324 | monoscale | 1 |
| 325 | monthly-supervised | 1 |
| 326 | mosque | 1 |
| 327 | motility-recovery | 1 |
| 328 | motorsport | 1 |
| 329 | mucoprotective | 1 |
| 330 | multi-channel-blocking | 1 |
| 331 | multilevel-approach | 1 |
| 332 | multiparasiticidal | 1 |
| 333 | myb-containing | 1 |
| 334 | myoprotective | 1 |
| 335 | nafld-triggering | 1 |
| 336 | nebivolol-based | 1 |
| 337 | never-before-presented | 1 |
| 338 | nibi3-type | 1 |
| 339 | no-antithrombotics | 1 |
| 340 | non-anti-inflammatory | 1 |
| 341 | non-booster | 1 |
| 342 | non-intoxicating | 1 |
| 343 | non-mars | 1 |
| 344 | non-plastic | 1 |
| 345 | non-radioisotope-labeled | 1 |
| 346 | noncaring | 1 |
| 347 | nonfibrin-specific | 1 |
| 348 | nongesturing | 1 |
| 349 | nonselective-blocking | 1 |
| 350 | nonsuch | 1 |
| 351 | nurse/midwife | 1 |
| 352 | once-every-month | 1 |
| 353 | once-nightly | 1 |
| 354 | original-formulation | 1 |
| 355 | osseointe-grated | 1 |
| 356 | p.tyr666cys | 1 |
| 357 | p226l | 1 |
| 358 | pan-high | 1 |
| 359 | pcb-contaminated | 1 |
| 360 | pebbled | 1 |
| 361 | peg400/labrasol | 1 |
| 362 | percutaneous-placed | 1 |
| 363 | peripheral- | 1 |
| 364 | perylene-dominated | 1 |
| 365 | pgl4-sre | 1 |
| 366 | phantom-filled | 1 |
| 367 | phregulating | 1 |
| 368 | placebo-block/scopolamine-block | 1 |
| 369 | placebo/loading | 1 |
| 370 | placido-based | 1 |
| 371 | playlist | 1 |
| 372 | pmcn | 1 |
| 373 | poisoner | 1 |
| 374 | postthymic | 1 |
| 375 | pre-bonta | 1 |
| 376 | procholinergic | 1 |
| 377 | pseudo-centrosymmetric | 1 |
| 378 | pseudo-viral | 1 |
| 379 | pseudoephedrine-containing | 1 |
| 380 | pseudogymnoascus | 1 |
| 381 | pulp-devitalized | 1 |
| 382 | pyelocutaneostomy | 1 |
| 383 | quality/efficiency | 1 |
| 384 | ra-226 | 1 |
| 385 | ra1/5+b | 1 |
| 386 | radiochemotherapy-induced | 1 |
| 387 | rapidly-bactericidal | 1 |
| 388 | remifentanil- | 1 |
| 389 | response/stabilization | 1 |
| 390 | retention-enhancing | 1 |
| 391 | right-located | 1 |
| 392 | rituximab+a | 1 |
| 393 | saphena-femoral | 1 |
| 394 | saponin-free | 1 |
| 395 | sc-administered | 1 |
| 396 | self-regulation-depletion | 1 |
| 397 | semicolon | 1 |
| 398 | semiconscious | 1 |
| 399 | sensitivity-driven | 1 |
| 400 | sensory-integration | 1 |
| 401 | serotonergic-depleting | 1 |
| 402 | sham-device | 1 |
| 403 | sheath.a | 1 |
| 404 | shopkeeper | 1 |
| 405 | single-adjuvanted | 1 |
| 406 | single-agonist | 1 |
| 407 | single-capillary | 1 |
| 408 | single/combination | 1 |
| 409 | six-to-eight | 1 |
| 410 | specialist-certified | 1 |
| 411 | squeaky-clean | 1 |
| 412 | srl- | 1 |
| 413 | stimulated-recall | 1 |
| 414 | stool-bulking | 1 |
| 415 | strong-weak | 1 |
| 416 | sub-antihypertensive | 1 |
| 417 | sub-occlusion | 1 |
| 418 | sub-ureteral | 1 |
| 419 | subject-first | 1 |
| 420 | subovulatory | 1 |
| 421 | subparalytic | 1 |
| 422 | subphenotypical | 1 |
| 423 | sun-drenched | 1 |
| 424 | sunhat | 1 |
| 425 | supportive- | 1 |
| 426 | t2-contrast | 1 |
| 427 | take-then-cure | 1 |
| 428 | tamponading | 1 |
| 429 | tannin-reactive | 1 |
| 430 | teacher-implemented | 1 |
| 431 | teritary | 1 |
| 432 | thiol-blocking | 1 |
| 433 | three-day-averaged | 1 |
| 434 | three-lever | 1 |
| 435 | three-room | 1 |
| 436 | thrice-per-week | 1 |
| 437 | thymidine-dependent | 1 |
| 438 | time-profiled | 1 |
| 439 | to-be-stolen | 1 |
| 440 | tramadol-alone | 1 |
| 441 | transorotracheal | 1 |
| 442 | trauma- | 1 |
| 443 | troublemaker | 1 |
| 444 | tumor-seeking | 1 |
| 445 | turtle-bearing | 1 |
| 446 | two-gram | 1 |
| 447 | type3-like | 1 |
| 448 | unometer | 1 |
| 449 | vortex-cooled | 1 |
| 450 | w-box-containing | 1 |
| 451 | watt-level | 1 |
| 452 | weight-only | 1 |
| 453 | whole-grain-based | 1 |
| 454 | yelp | 1 |
| 455 | yycf-activated | 1 |
| 456 | zaleplon-induced | 1 |
| 457 | zero-gradient | 1 |
| 458 | ±≤2 | 1 |
| 459 | μ1,2 | 1 |
| 460 | “silent | 1 |
| 461 | ≥6-d | 1 |
| 1 | 'kneeling | 1 |
| 2 | 'wonder | 1 |
| 3 | +3-line | 1 |
| 4 | -3.00d | 2 |
| 5 | 0.25-mg/kg | 1 |
| 6 | 1,200-mg | 3 |
| 7 | 1,300-mg | 1 |
| 8 | 1-time | 19 |
| 9 | 1.25-mm | 2 |
| 10 | 1.5-mg/kg | 1 |
| 11 | 1.5-ml | 4 |
| 12 | 10,000xg | 1 |
| 13 | 10-ng/kg/min | 1 |
| 14 | 10.9-fold | 1 |
| 15 | 100-db | 1 |
| 16 | 100-gram | 2 |
| 17 | 100-µg | 1 |
| 18 | 12-μg/kg | 1 |
| 19 | 1200-kcal | 2 |
| 20 | 122-bed | 1 |
| 21 | 1250-bed | 1 |
| 22 | 1300-bed | 1 |
| 23 | 138-mg | 1 |
| 24 | 14-gy | 2 |
| 25 | 15-hour | 4 |
| 26 | 15-mg/kg/day | 1 |
| 27 | 150,000-iu | 1 |
| 28 | 16-amino-acid | 1 |
| 29 | 16-oz | 3 |
| 30 | 1740bp | 1 |
| 31 | 180-microg/kg | 2 |
| 32 | 2-bromobenzyl | 1 |
| 33 | 2-ml | 11 |
| 34 | 2-time | 3 |
| 35 | 2.3-kb | 5 |
| 36 | 2.5-mcg/kg | 1 |
| 37 | 2.5-mg/kg | 1 |
| 38 | 2.5-ml | 6 |
| 39 | 2.5-yr-old | 1 |
| 40 | 2.5-μg | 1 |
| 41 | 20-g | 14 |
| 42 | 20-ml | 11 |
| 43 | 20-ml/kg | 1 |
| 44 | 21-g | 2 |
| 45 | 2200-bed | 1 |
| 46 | 240-minute | 1 |
| 47 | 250-microg | 1 |
| 48 | 256-detector | 1 |
| 49 | 26-gauge | 2 |
| 50 | 270-bed | 1 |
| 51 | 2990-bed | 1 |
| 52 | 3'-nuclease-resistant | 1 |
| 53 | 3-day-treatment | 1 |
| 54 | 3-day/month | 2 |
| 55 | 3-log10 | 2 |
| 56 | 3-microg/kg | 1 |
| 57 | 3-nmol | 1 |
| 58 | 30-cycle | 3 |
| 59 | 30-lead | 2 |
| 60 | 30-session | 1 |
| 61 | 34-mg | 1 |
| 62 | 4,000-u | 1 |
| 63 | 4-gy | 2 |
| 64 | 4-hospital | 1 |
| 65 | 4-substituent | 1 |
| 66 | 40-mcg | 1 |
| 67 | 40-microgram/kg | 1 |
| 68 | 45-60-second | 1 |
| 69 | 480-khz | 2 |
| 70 | 5,000-u | 1 |
| 71 | 5-g | 9 |
| 72 | 5-ml | 22 |
| 73 | 5-propynyl | 1 |
| 74 | 50-iu/kg | 1 |
| 75 | 500-micrograms | 1 |
| 76 | 50ms | 1 |
| 77 | 50μg | 1 |
| 78 | 6-microg/kg | 1 |
| 79 | 6-nmol | 1 |
| 80 | 60-ml | 8 |
| 81 | 7.5-mm | 5 |
| 82 | 7.5-µg | 3 |
| 83 | 75-g | 81 |
| 84 | 75-gram | 11 |
| 85 | 75-microgram | 1 |
| 86 | 75-unit | 1 |
| 87 | 75g | 5 |
| 88 | 95-kda | 1 |
| 89 | 955-bed | 1 |
| 90 | afatinib-an | 1 |
| 91 | allylborating | 1 |
| 92 | antipicornavirus | 1 |
| 93 | babysitter | 1 |
| 94 | ballpoint | 7 |
| 95 | basal-supported | 2 |
| 96 | bb-2 | 1 |
| 97 | beadxpress | 1 |
| 98 | benzisoxazole | 4 |
| 99 | beta-1-selective | 2 |
| 100 | beta-blocker.the | 1 |
| 101 | beta-blocker/sympatholytic | 1 |
| 102 | beta-lactamic | 1 |
| 103 | beta-lowering | 1 |
| 104 | betacytotoxic | 1 |
| 105 | better-assessed | 1 |
| 106 | biflavone | 1 |
| 107 | bioenterics | 18 |
| 108 | bolus-loading | 1 |
| 109 | breath-synchronized | 1 |
| 110 | buthanolic | 1 |
| 111 | c.592_593dup | 1 |
| 112 | c7-ketone | 1 |
| 113 | calcium-complexing | 1 |
| 114 | carbamate- | 1 |
| 115 | carbapenem-sparing | 1 |
| 116 | carbon-11-labelled | 1 |
| 117 | caregiver-adolescent | 1 |
| 118 | central-cavity | 1 |
| 119 | chain-terminating | 2 |
| 120 | chemosensitising | 1 |
| 121 | choriocentesis | 1 |
| 122 | church-organized | 1 |
| 123 | citalopram/escitalopram | 1 |
| 124 | co-spouse | 1 |
| 125 | co-suspect | 2 |
| 126 | collagen/epinephrine- | 1 |
| 127 | collodion | 2 |
| 128 | commoditised | 1 |
| 129 | compressor/nebulizer | 1 |
| 130 | contrast-training | 1 |
| 131 | cooking-course | 1 |
| 132 | coordinated-delivery | 2 |
| 133 | corrupting | 1 |
| 134 | corticosteroid-sensitizing | 1 |
| 135 | court-appointed | 1 |
| 136 | cox-2-targeting | 1 |
| 137 | critical-dose | 2 |
| 138 | cwep | 1 |
| 139 | cyclizing | 3 |
| 140 | cysteine-modifying | 1 |
| 141 | dat-blocking | 1 |
| 142 | data-coordinating | 3 |
| 143 | day/1 | 1 |
| 144 | demineralising | 2 |
| 145 | dense-sampling | 1 |
| 146 | dettol | 1 |
| 147 | dexmedetomidine- | 1 |
| 148 | dextrose-containing | 1 |
| 149 | diagnodent® | 1 |
| 150 | direct-liquid | 1 |
| 151 | disparity- | 1 |
| 152 | dopamine-receptor-blocking | 1 |
| 153 | doregfp | 1 |
| 154 | double-j-stent | 1 |
| 155 | double-standard | 1 |
| 156 | downward-pointing | 2 |
| 157 | doxepin-treated | 1 |
| 158 | dsm-iii/iv | 2 |
| 159 | dsred-monomer | 1 |
| 160 | dtp-hbv | 1 |
| 161 | dtrpa1-c/d | 1 |
| 162 | ether-extractable | 2 |
| 163 | eudragit®-based | 1 |
| 164 | explicative | 3 |
| 165 | fa-lowering | 1 |
| 166 | fast-speaking | 1 |
| 167 | fenbendazole-containing | 1 |
| 168 | fetocidal | 1 |
| 169 | first/last | 2 |
| 170 | fistula/leak | 1 |
| 171 | five-bladed | 2 |
| 172 | five-time | 1 |
| 173 | fixed-flexible | 5 |
| 174 | flow-diverter | 1 |
| 175 | flow-type | 2 |
| 176 | fluopyrimidine | 1 |
| 177 | fluorescence- | 1 |
| 178 | fluoroscopy- | 1 |
| 179 | food-tasting | 1 |
| 180 | four-phasic | 2 |
| 181 | fourth-dose | 2 |
| 182 | full-day | 13 |
| 183 | g3-c12-mediated | 1 |
| 184 | gasoline-equivalent | 1 |
| 185 | geometric-shape | 1 |
| 186 | germline-specific | 4 |
| 187 | gfp-hit4 | 1 |
| 188 | giraffe | 7 |
| 189 | glutathione-binding | 1 |
| 190 | glycine-based | 4 |
| 191 | gold-containing | 1 |
| 192 | governmentally-led | 1 |
| 193 | grass/rye | 1 |
| 194 | greater-risk | 1 |
| 195 | growth/cell-cycle-suppressing | 1 |
| 196 | gsh-dependent | 1 |
| 197 | gsm-modulated | 1 |
| 198 | gy-full | 1 |
| 199 | harelipped | 1 |
| 200 | health-club | 1 |
| 201 | heroin-abusing | 1 |
| 202 | herpes-infected | 1 |
| 203 | hexadecylamine | 1 |
| 204 | high-affinity-low-capacity | 1 |
| 205 | high-caliber | 2 |
| 206 | high-fat/low-fiber | 1 |
| 207 | high-polyunsaturated | 1 |
| 208 | high/luteolytic | 1 |
| 209 | higher-than-equivalent | 1 |
| 210 | higher-than-replacement | 2 |
| 211 | human-voiced | 1 |
| 212 | hyperfluorescent | 3 |
| 213 | hypergammaglobulinemic | 1 |
| 214 | hypo-echoic | 1 |
| 215 | hypocholestrolemic | 1 |
| 216 | hypolipodemic | 1 |
| 217 | impdh2 | 1 |
| 218 | intravenous/ | 1 |
| 219 | judo-training | 2 |
| 220 | kerosene-based | 1 |
| 221 | knife/gun | 1 |
| 222 | koshu | 1 |
| 223 | label-claimed | 2 |
| 224 | laboratory-driven | 1 |
| 225 | laterally-shifted | 1 |
| 226 | lateroventral | 2 |
| 227 | leg- | 1 |
| 228 | lensed | 1 |
| 229 | letrozole-to-tamoxifen | 1 |
| 230 | leuko-depleting | 1 |
| 231 | lianous | 1 |
| 232 | lichrospher | 3 |
| 233 | light-drinking | 1 |
| 234 | limited-spectrum | 1 |
| 235 | linear-nodular | 1 |
| 236 | linear-plateau | 1 |
| 237 | lombotomy | 1 |
| 238 | low-dietary | 3 |
| 239 | low-experience | 1 |
| 240 | low-phonon-energy | 1 |
| 241 | lower-than-approved | 1 |
| 242 | luciferase-based | 1 |
| 243 | m42 | 2 |
| 244 | macintosh-style | 1 |
| 245 | magnetothermal | 1 |
| 246 | manic/hypomanic/mixed | 1 |
| 247 | mantram-a | 1 |
| 248 | marker-single | 1 |
| 249 | market-leading | 2 |
| 250 | mastery- | 1 |
| 251 | maternal-care | 1 |
| 252 | medium-low | 5 |
| 253 | megafilling | 2 |
| 254 | methanol-chcl3 | 1 |
| 255 | metronidazole/aminoglycoside | 1 |
| 256 | micro-oxidative | 1 |
| 257 | microsequential | 2 |
| 258 | microsome-enriched | 2 |
| 259 | mimivirus-like | 1 |
| 260 | mohel* | 1 |
| 261 | mono/dual | 1 |
| 262 | monoagent | 1 |
| 263 | monoscale | 1 |
| 264 | monthly-supervised | 1 |
| 265 | mosque | 1 |
| 266 | motility-recovery | 1 |
| 267 | motorsport | 1 |
| 268 | mucoprotective | 1 |
| 269 | multi-channel-blocking | 1 |
| 270 | multi-compartment | 3 |
| 271 | multilevel-approach | 1 |
| 272 | multiparasiticidal | 1 |
| 273 | multipathogen | 2 |
| 274 | muscle/fat | 2 |
| 275 | myb-containing | 1 |
| 276 | myoprotective | 1 |
| 277 | nafld-triggering | 1 |
| 278 | near-lethal | 4 |
| 279 | near-maximum | 2 |
| 280 | nebivolol-based | 1 |
| 281 | never-before-presented | 1 |
| 282 | nibi3-type | 1 |
| 283 | nicotinized | 2 |
| 284 | no-antithrombotics | 1 |
| 285 | non-anti-inflammatory | 1 |
| 286 | non-antihypertensive | 3 |
| 287 | non-booster | 1 |
| 288 | non-depressor | 2 |
| 289 | non-intoxicating | 1 |
| 290 | non-mars | 1 |
| 291 | non-oncology | 6 |
| 292 | non-plastic | 1 |
| 293 | non-radioisotope-labeled | 1 |
| 294 | nonamplifiable | 2 |
| 295 | nonantidepressant | 3 |
| 296 | noncaring | 1 |
| 297 | nonfibrin-specific | 1 |
| 298 | nongesturing | 1 |
| 299 | nonhypotensive | 3 |
| 300 | nonselective-blocking | 1 |
| 301 | nonsuch | 1 |
| 302 | nurse/midwife | 1 |
| 303 | once-every-month | 1 |
| 304 | once-nightly | 1 |
| 305 | one-time | 119 |
| 306 | original-formulation | 1 |
| 307 | osseointe-grated | 1 |
| 308 | p-stim® | 2 |
| 309 | p.tyr666cys | 1 |
| 310 | p226l | 1 |
| 311 | p4-releasing | 3 |
| 312 | pan-high | 1 |
| 313 | pcb-contaminated | 1 |
| 314 | pebbled | 1 |
| 315 | peg400/labrasol | 1 |
| 316 | percutaneous-placed | 1 |
| 317 | peripheral- | 1 |
| 318 | perylene-dominated | 1 |
| 319 | pgl4-sre | 1 |
| 320 | phantom-filled | 1 |
| 321 | phregulating | 1 |
| 322 | placebo-block/scopolamine-block | 1 |
| 323 | placebo/loading | 1 |
| 324 | placido-based | 1 |
| 325 | playlist | 1 |
| 326 | pmcn | 1 |
| 327 | poisoner | 1 |
| 328 | postthymic | 1 |
| 329 | pre-bonta | 1 |
| 330 | precurarizing | 3 |
| 331 | proanthocyanidin-rich | 2 |
| 332 | process- | 2 |
| 333 | procholinergic | 1 |
| 334 | pseudo-centrosymmetric | 1 |
| 335 | pseudo-viral | 1 |
| 336 | pseudoephedrine-containing | 1 |
| 337 | pseudogymnoascus | 1 |
| 338 | pulp-devitalized | 1 |
| 339 | pyelocutaneostomy | 1 |
| 340 | quality/efficiency | 1 |
| 341 | ra-226 | 1 |
| 342 | ra1/5+b | 1 |
| 343 | radiochemotherapy-induced | 1 |
| 344 | rapidly-bactericidal | 1 |
| 345 | reduced/tapering | 2 |
| 346 | remifentanil- | 1 |
| 347 | response-dependent | 3 |
| 348 | response/stabilization | 1 |
| 349 | retention-enhancing | 1 |
| 350 | right-located | 1 |
| 351 | risk-accepting | 4 |
| 352 | rituximab+a | 1 |
| 353 | rubrene | 2 |
| 354 | saphena-femoral | 1 |
| 355 | saponin-free | 1 |
| 356 | sc-administered | 1 |
| 357 | self-regulation-depletion | 1 |
| 358 | semi-open | 9 |
| 359 | semicolon | 1 |
| 360 | semiconscious | 1 |
| 361 | sensitivity-driven | 1 |
| 362 | sensory-integration | 1 |
| 363 | serotonergic-depleting | 1 |
| 364 | sham-device | 1 |
| 365 | sheath.a | 1 |
| 366 | shofu | 4 |
| 367 | shopkeeper | 1 |
| 368 | simulation-enhanced | 3 |
| 369 | singe | 4 |
| 370 | single | 27,642 |
| 371 | single-active | 4 |
| 372 | single-adjuvanted | 1 |
| 373 | single-agonist | 1 |
| 374 | single-ascending | 15 |
| 375 | single-capillary | 1 |
| 376 | single-oral | 5 |
| 377 | single-quadripolar | 2 |
| 378 | single-rising | 2 |
| 379 | single-strength | 3 |
| 380 | single-threshold | 3 |
| 381 | single/combination | 1 |
| 382 | six-time | 3 |
| 383 | six-to-eight | 1 |
| 384 | size-4 | 2 |
| 385 | sound-head | 2 |
| 386 | specialist-certified | 1 |
| 387 | species’ | 2 |
| 388 | squeaky-clean | 1 |
| 389 | srl- | 1 |
| 390 | standard-higher | 4 |
| 391 | stimulated-recall | 1 |
| 392 | stool-bulking | 1 |
| 393 | strong-weak | 1 |
| 394 | structure-directing | 8 |
| 395 | study-logo | 2 |
| 396 | sub-antihypertensive | 1 |
| 397 | sub-effective | 9 |
| 398 | sub-occlusion | 1 |
| 399 | sub-ureteral | 1 |
| 400 | subantibiotic | 4 |
| 401 | subdepressor | 4 |
| 402 | subeffective | 6 |
| 403 | subhypnotic | 8 |
| 404 | subject-first | 1 |
| 405 | subovulatory | 1 |
| 406 | subparalytic | 1 |
| 407 | subphenotypical | 1 |
| 408 | subpressor | 2 |
| 409 | subpurpuragenic | 2 |
| 410 | subterminal | 4 |
| 411 | sun-drenched | 1 |
| 412 | sunhat | 1 |
| 413 | supportive- | 1 |
| 414 | t2-contrast | 1 |
| 415 | take-then-cure | 1 |
| 416 | tamponading | 1 |
| 417 | tannin-reactive | 1 |
| 418 | target-present | 2 |
| 419 | teacher-implemented | 1 |
| 420 | teflon-lined | 2 |
| 421 | ten-month-old | 2 |
| 422 | teritary | 1 |
| 423 | therapist-applied | 2 |
| 424 | thiol-blocking | 1 |
| 425 | three-axis | 3 |
| 426 | three-day-averaged | 1 |
| 427 | three-lever | 1 |
| 428 | three-room | 1 |
| 429 | thrice-per-week | 1 |
| 430 | thymidine-dependent | 1 |
| 431 | time-profiled | 1 |
| 432 | to-be-stolen | 1 |
| 433 | tong-mai | 2 |
| 434 | too-high | 2 |
| 435 | tramadol-alone | 1 |
| 436 | transorotracheal | 1 |
| 437 | trauma- | 1 |
| 438 | treatment-blind | 3 |
| 439 | troublemaker | 1 |
| 440 | trp-balanced | 3 |
| 441 | tumor-seeking | 1 |
| 442 | tumoristatic | 4 |
| 443 | turtle-bearing | 1 |
| 444 | two-gram | 1 |
| 445 | type3-like | 1 |
| 446 | unometer | 1 |
| 447 | visual-to-auditory | 2 |
| 448 | vortex-cooled | 1 |
| 449 | w-box-containing | 1 |
| 450 | watt-level | 1 |
| 451 | weight-only | 1 |
| 452 | whole-grain-based | 1 |
| 453 | wound-irrigation | 2 |
| 454 | yelp | 1 |
| 455 | yycf-activated | 1 |
| 456 | zaleplon-induced | 1 |
| 457 | zero-gradient | 1 |
| 458 | ±≤2 | 1 |
| 459 | μ1,2 | 1 |
| 460 | “silent | 1 |
| 461 | ≥6-d | 1 |
| 1 | mohel* | 1 |
| 2 | trauma- | 1 |
| 3 | fluorescence- | 1 |
| 4 | dexmedetomidine- | 1 |
| 5 | collagen/epinephrine- | 1 |
| 6 | carbamate- | 1 |
| 7 | supportive- | 1 |
| 8 | leg- | 1 |
| 9 | peripheral- | 1 |
| 10 | remifentanil- | 1 |
| 11 | srl- | 1 |
| 12 | process- | 2 |
| 13 | fluoroscopy- | 1 |
| 14 | mastery- | 1 |
| 15 | disparity- | 1 |
| 16 | intravenous/ | 1 |
| 17 | 3-log10 | 2 |
| 18 | day/1 | 1 |
| 19 | μ1,2 | 1 |
| 20 | bb-2 | 1 |
| 21 | m42 | 2 |
| 22 | impdh2 | 1 |
| 23 | ±≤2 | 1 |
| 24 | methanol-chcl3 | 1 |
| 25 | size-4 | 2 |
| 26 | gfp-hit4 | 1 |
| 27 | ra-226 | 1 |
| 28 | rituximab+a | 1 |
| 29 | mantram-a | 1 |
| 30 | sheath.a | 1 |
| 31 | 95-kda | 1 |
| 32 | pre-bonta | 1 |
| 33 | ra1/5+b | 1 |
| 34 | 100-db | 1 |
| 35 | 2.3-kb | 5 |
| 36 | health-club | 1 |
| 37 | germline-specific | 4 |
| 38 | nonfibrin-specific | 1 |
| 39 | procholinergic | 1 |
| 40 | buthanolic | 1 |
| 41 | beta-lactamic | 1 |
| 42 | hypolipodemic | 1 |
| 43 | hypocholestrolemic | 1 |
| 44 | hypergammaglobulinemic | 1 |
| 45 | postthymic | 1 |
| 46 | subpurpuragenic | 2 |
| 47 | hypo-echoic | 1 |
| 48 | pseudo-centrosymmetric | 1 |
| 49 | four-phasic | 2 |
| 50 | tumoristatic | 4 |
| 51 | subantibiotic | 4 |
| 52 | subhypnotic | 8 |
| 53 | non-plastic | 1 |
| 54 | subparalytic | 1 |
| 55 | high/luteolytic | 1 |
| 56 | beta-blocker/sympatholytic | 1 |
| 57 | betacytotoxic | 1 |
| 58 | ≥6-d | 1 |
| 59 | dtrpa1-c/d | 1 |
| 60 | -3.00d | 2 |
| 61 | sound-head | 2 |
| 62 | 30-lead | 2 |
| 63 | 2200-bed | 1 |
| 64 | 1300-bed | 1 |
| 65 | 1250-bed | 1 |
| 66 | 270-bed | 1 |
| 67 | 2990-bed | 1 |
| 68 | 122-bed | 1 |
| 69 | 955-bed | 1 |
| 70 | percutaneous-placed | 1 |
| 71 | human-voiced | 1 |
| 72 | simulation-enhanced | 3 |
| 73 | trp-balanced | 3 |
| 74 | zaleplon-induced | 1 |
| 75 | radiochemotherapy-induced | 1 |
| 76 | five-bladed | 2 |
| 77 | three-day-averaged | 1 |
| 78 | microsome-enriched | 2 |
| 79 | sun-drenched | 1 |
| 80 | specialist-certified | 1 |
| 81 | therapist-applied | 2 |
| 82 | governmentally-led | 1 |
| 83 | pebbled | 1 |
| 84 | non-radioisotope-labeled | 1 |
| 85 | time-profiled | 1 |
| 86 | carbon-11-labelled | 1 |
| 87 | phantom-filled | 1 |
| 88 | vortex-cooled | 1 |
| 89 | label-claimed | 2 |
| 90 | teflon-lined | 2 |
| 91 | harelipped | 1 |
| 92 | sc-administered | 1 |
| 93 | kerosene-based | 1 |
| 94 | glycine-based | 4 |
| 95 | luciferase-based | 1 |
| 96 | nebivolol-based | 1 |
| 97 | whole-grain-based | 1 |
| 98 | placido-based | 1 |
| 99 | eudragit®-based | 1 |
| 100 | commoditised | 1 |
| 101 | monthly-supervised | 1 |
| 102 | lensed | 1 |
| 103 | better-assessed | 1 |
| 104 | right-located | 1 |
| 105 | doxepin-treated | 1 |
| 106 | g3-c12-mediated | 1 |
| 107 | gsm-modulated | 1 |
| 108 | pcb-contaminated | 1 |
| 109 | perylene-dominated | 1 |
| 110 | osseointe-grated | 1 |
| 111 | high-polyunsaturated | 1 |
| 112 | yycf-activated | 1 |
| 113 | herpes-infected | 1 |
| 114 | laterally-shifted | 1 |
| 115 | single-adjuvanted | 1 |
| 116 | teacher-implemented | 1 |
| 117 | never-before-presented | 1 |
| 118 | court-appointed | 1 |
| 119 | basal-supported | 2 |
| 120 | lower-than-approved | 1 |
| 121 | manic/hypomanic/mixed | 1 |
| 122 | pulp-devitalized | 1 |
| 123 | church-organized | 1 |
| 124 | nicotinized | 2 |
| 125 | breath-synchronized | 1 |
| 126 | 16-amino-acid | 1 |
| 127 | direct-liquid | 1 |
| 128 | ten-month-old | 2 |
| 129 | 2.5-yr-old | 1 |
| 130 | 10.9-fold | 1 |
| 131 | single-threshold | 3 |
| 132 | treatment-blind | 3 |
| 133 | 45-60-second | 1 |
| 134 | double-standard | 1 |
| 135 | sham-device | 1 |
| 136 | low-experience | 1 |
| 137 | metronidazole/aminoglycoside | 1 |
| 138 | saponin-free | 1 |
| 139 | giraffe | 7 |
| 140 | nurse/midwife | 1 |
| 141 | singe | 4 |
| 142 | 26-gauge | 2 |
| 143 | beta-blocker.the | 1 |
| 144 | type3-like | 1 |
| 145 | mimivirus-like | 1 |
| 146 | monoscale | 1 |
| 147 | nonamplifiable | 2 |
| 148 | ether-extractable | 2 |
| 149 | fixed-flexible | 5 |
| 150 | 30-cycle | 3 |
| 151 | single | 27,642 |
| 152 | marker-single | 1 |
| 153 | benzisoxazole | 4 |
| 154 | macintosh-style | 1 |
| 155 | 1-time | 19 |
| 156 | 2-time | 3 |
| 157 | one-time | 119 |
| 158 | five-time | 1 |
| 159 | six-time | 3 |
| 160 | rubrene | 2 |
| 161 | fluopyrimidine | 1 |
| 162 | +3-line | 1 |
| 163 | hexadecylamine | 1 |
| 164 | tramadol-alone | 1 |
| 165 | c7-ketone | 1 |
| 166 | biflavone | 1 |
| 167 | geometric-shape | 1 |
| 168 | nibi3-type | 1 |
| 169 | flow-type | 2 |
| 170 | maternal-care | 1 |
| 171 | pgl4-sre | 1 |
| 172 | take-then-cure | 1 |
| 173 | fourth-dose | 2 |
| 174 | critical-dose | 2 |
| 175 | cooking-course | 1 |
| 176 | co-spouse | 1 |
| 177 | 240-minute | 1 |
| 178 | mosque | 1 |
| 179 | nonhypotensive | 3 |
| 180 | sub-antihypertensive | 1 |
| 181 | non-antihypertensive | 3 |
| 182 | explicative | 3 |
| 183 | micro-oxidative | 1 |
| 184 | single-active | 4 |
| 185 | tannin-reactive | 1 |
| 186 | sub-effective | 9 |
| 187 | subeffective | 6 |
| 188 | beta-1-selective | 2 |
| 189 | mucoprotective | 1 |
| 190 | myoprotective | 1 |
| 191 | grass/rye | 1 |
| 192 | 20-g | 14 |
| 193 | 21-g | 2 |
| 194 | 5-g | 9 |
| 195 | 75-g | 81 |
| 196 | 75g | 5 |
| 197 | 40-mcg | 1 |
| 198 | 2.5-mcg/kg | 1 |
| 199 | 1.5-mg/kg | 1 |
| 200 | 2.5-mg/kg | 1 |
| 201 | 0.25-mg/kg | 1 |
| 202 | 180-microg/kg | 2 |
| 203 | 3-microg/kg | 1 |
| 204 | 6-microg/kg | 1 |
| 205 | 12-μg/kg | 1 |
| 206 | 20-ml/kg | 1 |
| 207 | 40-microgram/kg | 1 |
| 208 | 50-iu/kg | 1 |
| 209 | 1,200-mg | 3 |
| 210 | 1,300-mg | 1 |
| 211 | 34-mg | 1 |
| 212 | 138-mg | 1 |
| 213 | retention-enhancing | 1 |
| 214 | market-leading | 2 |
| 215 | tamponading | 1 |
| 216 | bolus-loading | 1 |
| 217 | placebo/loading | 1 |
| 218 | single-ascending | 15 |
| 219 | glutathione-binding | 1 |
| 220 | fast-speaking | 1 |
| 221 | nonselective-blocking | 1 |
| 222 | multi-channel-blocking | 1 |
| 223 | thiol-blocking | 1 |
| 224 | dopamine-receptor-blocking | 1 |
| 225 | dat-blocking | 1 |
| 226 | tumor-seeking | 1 |
| 227 | stool-bulking | 1 |
| 228 | light-drinking | 1 |
| 229 | 'kneeling | 1 |
| 230 | megafilling | 2 |
| 231 | dense-sampling | 1 |
| 232 | judo-training | 2 |
| 233 | contrast-training | 1 |
| 234 | myb-containing | 1 |
| 235 | gold-containing | 1 |
| 236 | fenbendazole-containing | 1 |
| 237 | pseudoephedrine-containing | 1 |
| 238 | dextrose-containing | 1 |
| 239 | w-box-containing | 1 |
| 240 | noncaring | 1 |
| 241 | turtle-bearing | 1 |
| 242 | carbapenem-sparing | 1 |
| 243 | nafld-triggering | 1 |
| 244 | reduced/tapering | 2 |
| 245 | fa-lowering | 1 |
| 246 | beta-lowering | 1 |
| 247 | nongesturing | 1 |
| 248 | p4-releasing | 3 |
| 249 | demineralising | 2 |
| 250 | single-rising | 2 |
| 251 | chemosensitising | 1 |
| 252 | growth/cell-cycle-suppressing | 1 |
| 253 | heroin-abusing | 1 |
| 254 | non-intoxicating | 1 |
| 255 | phregulating | 1 |
| 256 | data-coordinating | 3 |
| 257 | chain-terminating | 2 |
| 258 | allylborating | 1 |
| 259 | structure-directing | 8 |
| 260 | cox-2-targeting | 1 |
| 261 | serotonergic-depleting | 1 |
| 262 | leuko-depleting | 1 |
| 263 | downward-pointing | 2 |
| 264 | risk-accepting | 4 |
| 265 | corrupting | 1 |
| 266 | food-tasting | 1 |
| 267 | calcium-complexing | 1 |
| 268 | cysteine-modifying | 1 |
| 269 | cyclizing | 3 |
| 270 | precurarizing | 3 |
| 271 | corticosteroid-sensitizing | 1 |
| 272 | 250-microg | 1 |
| 273 | 10,000xg | 1 |
| 274 | 100-µg | 1 |
| 275 | 7.5-µg | 3 |
| 276 | 2.5-μg | 1 |
| 277 | 50μg | 1 |
| 278 | multilevel-approach | 1 |
| 279 | proanthocyanidin-rich | 2 |
| 280 | nonsuch | 1 |
| 281 | pan-high | 1 |
| 282 | too-high | 2 |
| 283 | single-strength | 3 |
| 284 | once-every-month | 1 |
| 285 | 3-day/month | 2 |
| 286 | tong-mai | 2 |
| 287 | fistula/leak | 1 |
| 288 | strong-weak | 1 |
| 289 | placebo-block/scopolamine-block | 1 |
| 290 | thrice-per-week | 1 |
| 291 | greater-risk | 1 |
| 292 | p226l | 1 |
| 293 | subphenotypical | 1 |
| 294 | 1200-kcal | 2 |
| 295 | rapidly-bactericidal | 1 |
| 296 | multiparasiticidal | 1 |
| 297 | fetocidal | 1 |
| 298 | transorotracheal | 1 |
| 299 | near-lethal | 4 |
| 300 | microsequential | 2 |
| 301 | magnetothermal | 1 |
| 302 | subterminal | 4 |
| 303 | sub-ureteral | 1 |
| 304 | pseudo-viral | 1 |
| 305 | single-oral | 5 |
| 306 | saphena-femoral | 1 |
| 307 | lateroventral | 2 |
| 308 | 4-hospital | 1 |
| 309 | mono/dual | 1 |
| 310 | watt-level | 1 |
| 311 | stimulated-recall | 1 |
| 312 | gy-full | 1 |
| 313 | 20-ml | 11 |
| 314 | 60-ml | 8 |
| 315 | 2-ml | 11 |
| 316 | 5-ml | 22 |
| 317 | 1.5-ml | 4 |
| 318 | 2.5-ml | 6 |
| 319 | 3-nmol | 1 |
| 320 | 6-nmol | 1 |
| 321 | peg400/labrasol | 1 |
| 322 | dettol | 1 |
| 323 | 5-propynyl | 1 |
| 324 | 2-bromobenzyl | 1 |
| 325 | 100-gram | 2 |
| 326 | 75-gram | 11 |
| 327 | two-gram | 1 |
| 328 | 75-microgram | 1 |
| 329 | citalopram/escitalopram | 1 |
| 330 | 7.5-mm | 5 |
| 331 | 1.25-mm | 2 |
| 332 | three-room | 1 |
| 333 | near-maximum | 2 |
| 334 | limited-spectrum | 1 |
| 335 | afatinib-an | 1 |
| 336 | squeaky-clean | 1 |
| 337 | pmcn | 1 |
| 338 | letrozole-to-tamoxifen | 1 |
| 339 | multipathogen | 2 |
| 340 | to-be-stolen | 1 |
| 341 | semi-open | 9 |
| 342 | laboratory-driven | 1 |
| 343 | sensitivity-driven | 1 |
| 344 | 10-ng/kg/min | 1 |
| 345 | collodion | 2 |
| 346 | 30-session | 1 |
| 347 | sub-occlusion | 1 |
| 348 | wound-irrigation | 2 |
| 349 | original-formulation | 1 |
| 350 | single/combination | 1 |
| 351 | sensory-integration | 1 |
| 352 | response/stabilization | 1 |
| 353 | self-regulation-depletion | 1 |
| 354 | semicolon | 1 |
| 355 | knife/gun | 1 |
| 356 | study-logo | 2 |
| 357 | 1740bp | 1 |
| 358 | cwep | 1 |
| 359 | doregfp | 1 |
| 360 | yelp | 1 |
| 361 | c.592_593dup | 1 |
| 362 | single-quadripolar | 2 |
| 363 | linear-nodular | 1 |
| 364 | high-fat/low-fiber | 1 |
| 365 | high-caliber | 2 |
| 366 | 'wonder | 1 |
| 367 | standard-higher | 4 |
| 368 | lichrospher | 3 |
| 369 | troublemaker | 1 |
| 370 | dsred-monomer | 1 |
| 371 | poisoner | 1 |
| 372 | shopkeeper | 1 |
| 373 | unometer | 1 |
| 374 | flow-diverter | 1 |
| 375 | non-booster | 1 |
| 376 | babysitter | 1 |
| 377 | three-lever | 1 |
| 378 | compressor/nebulizer | 1 |
| 379 | subpressor | 2 |
| 380 | non-depressor | 2 |
| 381 | subdepressor | 4 |
| 382 | 256-detector | 1 |
| 383 | 15-hour | 4 |
| 384 | bioenterics | 18 |
| 385 | no-antithrombotics | 1 |
| 386 | choriocentesis | 1 |
| 387 | three-axis | 3 |
| 388 | 50ms | 1 |
| 389 | 500-micrograms | 1 |
| 390 | non-mars | 1 |
| 391 | beadxpress | 1 |
| 392 | pseudogymnoascus | 1 |
| 393 | semiconscious | 1 |
| 394 | lianous | 1 |
| 395 | antipicornavirus | 1 |
| 396 | p.tyr666cys | 1 |
| 397 | muscle/fat | 2 |
| 398 | sunhat | 1 |
| 399 | co-suspect | 2 |
| 400 | six-to-eight | 1 |
| 401 | 75-unit | 1 |
| 402 | nonantidepressant | 3 |
| 403 | 3'-nuclease-resistant | 1 |
| 404 | caregiver-adolescent | 1 |
| 405 | hyperfluorescent | 3 |
| 406 | thymidine-dependent | 1 |
| 407 | response-dependent | 3 |
| 408 | gsh-dependent | 1 |
| 409 | monoagent | 1 |
| 410 | zero-gradient | 1 |
| 411 | gasoline-equivalent | 1 |
| 412 | higher-than-equivalent | 1 |
| 413 | “silent | 1 |
| 414 | higher-than-replacement | 2 |
| 415 | 3-day-treatment | 1 |
| 416 | multi-compartment | 3 |
| 417 | target-present | 2 |
| 418 | double-j-stent | 1 |
| 419 | 4-substituent | 1 |
| 420 | ballpoint | 7 |
| 421 | motorsport | 1 |
| 422 | first/last | 2 |
| 423 | t2-contrast | 1 |
| 424 | playlist | 1 |
| 425 | single-agonist | 1 |
| 426 | subject-first | 1 |
| 427 | 4,000-u | 1 |
| 428 | 5,000-u | 1 |
| 429 | linear-plateau | 1 |
| 430 | shofu | 4 |
| 431 | koshu | 1 |
| 432 | 150,000-iu | 1 |
| 433 | dtp-hbv | 1 |
| 434 | dsm-iii/iv | 2 |
| 435 | medium-low | 5 |
| 436 | full-day | 13 |
| 437 | 15-mg/kg/day | 1 |
| 438 | quality/efficiency | 1 |
| 439 | 4-gy | 2 |
| 440 | 14-gy | 2 |
| 441 | non-oncology | 6 |
| 442 | low-phonon-energy | 1 |
| 443 | weight-only | 1 |
| 444 | once-nightly | 1 |
| 445 | lombotomy | 1 |
| 446 | pyelocutaneostomy | 1 |
| 447 | single-capillary | 1 |
| 448 | low-dietary | 3 |
| 449 | teritary | 1 |
| 450 | coordinated-delivery | 2 |
| 451 | motility-recovery | 1 |
| 452 | subovulatory | 1 |
| 453 | non-anti-inflammatory | 1 |
| 454 | visual-to-auditory | 2 |
| 455 | high-affinity-low-capacity | 1 |
| 456 | central-cavity | 1 |
| 457 | 480-khz | 2 |
| 458 | 16-oz | 3 |
| 459 | species’ | 2 |
| 460 | p-stim® | 2 |
| 461 | diagnodent® | 1 |